Nomexor Plus Hct (Hydrochlorothiazide, Nebivolol)

Hydrochlorothiazide increases urine output by blocking sodium‑chloride reabsorption in the kidney, reducing fluid volume. Nebivolol selectively blocks β1‑adrenergic receptors, slowing heart rate and promoting nitric‑oxide‑mediated vasodilation. Together they lower peripheral resistance and cardiac output, resulting in a more pronounced antihypertensive effect.

The dose of Nomexor Plus Hct is individualized by the prescribing clinician based on the patient’s blood‑pressure readings, renal function, and overall health status. No fixed regimen is provided here; the prescriber will select the appropriate strength and frequency.

Safety data for hydrochlorothiazide and nebivolol in pregnancy and lactation are limited. The medication should only be used if the potential benefit justifies any potential risk to the fetus or infant, and it must be prescribed after a thorough risk‑benefit assessment by a healthcare professional.

To request Nomexor Plus Hct, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with single‑component agents, the combination of hydrochlorothiazide and nebivolol offers complementary mechanisms—diuresis and β‑blockade—allowing better blood‑pressure control in patients who need more than one class. It may reduce the number of pills required versus separate prescriptions, but individual response and tolerance vary.

Nomexor Plus Hct tablets should be stored at room temperature, below 25 °C, in their original packaging. Protect them from moisture, excessive heat and direct sunlight to maintain potency throughout the shelf life.

The medication is taken orally, usually with a glass of water. It is typically prescribed to be taken once daily, but the exact timing and whether it should be taken with food are determined by the prescribing clinician.

Serious risks include severe allergic reactions (anaphylaxis), significant electrolyte imbalances such as hyponatremia or hypokalemia, and rare occurrences of gout attacks or pancreatitis. Patients should seek immediate medical attention if they experience symptoms like swelling of the face, difficulty breathing, or severe abdominal pain.

Patients with known hypersensitivity to either hydrochlorothiazide or nebivolol, those with severe renal impairment, uncontrolled heart failure, or certain cardiac conduction disorders should avoid this medication. Additionally, individuals taking lithium or other β‑blockers without medical supervision should not use it.